Advertisement


Related Videos

Breast Cancer

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.

Breast Cancer

Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive axillary nodes who convert to ypN0 after neoadjuvant chemotherapy? NSABP B-51/RTOG 1304 a phase III trial.”

Breast Cancer

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:

•          B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab
•          B-51, on radiation to the chest wall
•          Alliance trial, on lymph node dissection

Breast Cancer

Hope S. Rugo, MD, on the Phase II FIRST Study

Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S6-04, “Fulvestrant 500 mg vs anastrozole as first-line treatment for advanced breast cancer: Overall survival from the phase II FIRST study,” presented by John F.R. Robertson, MD.

Breast Cancer

Edith A. Perez, MD, on Stromal Tumor-Infiltrating Lymphocytes in Early-Stage HER2-Positive Breast Cancer

Edith A. Perez, MD, of the Mayo Clinic Cancer Center, discusses abstract S1-06, “Stromal tumor-infiltrating lymphocytes: In the Alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit.”

Advertisement

Advertisement




Advertisement